Almost 23 years ago, the first published report indicating that conventional, acidic, glucose-containing, lactate-buffered peritoneal dialysis solutions (PDF) inhibited many of the vital functions of leukocytes created the "science" of PDF biocompatibility [1] . In the proceeding decade, these initial seminal observations were developed and extended, initially to include characterization of the responsible components [2] [3] [4] [5] , and thereafter, the cellular mechanisms by which these PDF components modulated leukocyte and mesothelial cell function [6] [7] [8] [9] [10] [11] .
The initial studies were all characterized by a focus on the now well-described inhibitory effects of PDF components (or combinations thereof) on cell function. This Key words: biocompatibility, peritoneal macrophages (PMØ, host defense, inflammation, peritoneal membrane. C 2003 by the International Society of Nephrology research identified pH, high lactate concentration, hyperosmolality, glucose, and glucose degradation products as major effectors [3, 6, 7, 12] . Over the past decade, the focus of in vitro and, more recently, rodent studies has undergone a transition from one focusing principally on the effects of PDF on host defense to one that seeks to understand the causes of degenerative changes in the peritoneal membrane (see Williams et al, this supplement) [13, 14] . These investigations often have concentrated on glucose as a major activator of profibrogenic processes in the mesothelium, but also have identified the contribution of hyperosmolality and lactate concentrations in modulating the processes of cell activation related to the perpetuation of inflammation [15] [16] [17] [18] [19] [20] .
The data generated from in vitro biocompatibility studies have generally substantiated the hypothesis that conventional PDF, despite providing adequate dialysis, possess characteristics that might contribute to peritoneal membrane changes that over time can limit the long-term successful functioning of the peritoneal membrane. Furthermore, we now understand that infection, its associated inflammation, and exposure to conventional solutions, can all contribute directly or indirectly to changes in peritoneal membrane structure and function [14, 21] . This has led in the past few years to the development of new solutions designed with improved biocompatibility as their key feature.
THE NEED TO EVALUATE THE IMPACT OF SOLUTIONS IN VIVO
In principle, it can be argued that conventional in vitro testing, although providing important mechanistic insights into solution effects on various cell types, does not address the central issue of whether new dialysis solutions will result in improved in vivo performance. Our greater understanding of the processes that drive degenerative membrane changes during peritoneal dialysis (PD) require that we provide in vivo evidence of improved S- 84 peritoneal host defense and reduced inflammation and data demonstrating preservation of the peritoneal membrane. Ultimately, clinical outcome data are needed to establish improved efficacy of new solutions in long-term PD. Although appropriately powered studies will be required to correctly answer this latter question, the past few years have seen the development of ex vivo studies that have provided in vivo indications of improved performance of the new solutions. The findings of these studies and their implications will be discussed in the context of the current understanding of those factors that contribute to peritoneal membrane and host defense dysfunction in PD patients.
UNDERSTANDING THE IMPACT OF SOLUTIONS ON PERITONEAL HOST DEFENSE
Much of the early data generated in biocompatibility studies was related to the consensus that preservation of host defense was a key goal in PD patients. Infection remains the major reason for treatment failure. It is now also accepted that frequent or severe episodes of peritonitis and its associated inflammation contribute directly to membrane dysfunction [21] . Clearly implied in the published body of in vitro biocompatibility data is the link between exposure of cells to unphysiologic solutions, impairment of cell function, and ultimately compromised host defense.
The peritoneal cavity is normally a closed organ system that effectively manages infectious insult. Frank peritonitis occurs rarely in normal individuals and usually is associated with appendicitis, bowel perforation, or abdominal surgery. However, once activated, a sophisticated array of humoral and cellular host defense mechanisms combine to limit and clear infection [22] . In PD patients, although the effectors and mediators involved in peritoneal host defense are the same as in normal individuals, it is well established that host defense is compromised. This is likely due to the presence of an indwelling catheter that provides a portal of entry to microorganisms (primarily skin commencals such as Staphylococcal species) and to the large volume of infused dialysate that both reduces the likelihood of cell/pathogen interaction and dilutes humoral mediators (antibodies, complement, and other opsonins) [23] [24] [25] . Biocompatibility research has been central in characterizing the biology of the peritoneal cavity by identifying that its cellular components (both resident and infiltrating cells) play a pivotal role in host defense, and that infusion of unphysiologic solutions plays a key role in modulating the normal behavior of these components [26] [27] [28] [29] [30] .
It is now well established that the resident cells of the peritoneal cavity, the mesothelial cells and resident leukocytes, orchestrate the peritoneum's response to infection [29, 30] . Together with infiltrating leukocytes, the current paradigm of host response to bacterial contamination (derived from both studies in PD patients and animal models) suggests that while resident leukocytes initiate the process of inflammation through secretion of proinflammatory mediators such as interleukin (IL)-1, tumor necrosis factor (TNF), IL-17, and interferon (IFN)-c , the mesothelium acts as the central gatekeeper by directing and amplifying the recruitment of specific leukocyte phenotypes (initially neutrophils and subsequently mononuclear cells) through the controlled secretion of specific chemotactic cytokines [31] [32] [33] [34] [35] [36] [37] [38] [39] . Thereafter, acute inflammation is resolved by the downregulation of chemokine secretion and the promotion of leukocyte apoptosis that seems to be under the control of IL-6 and soluble IL-6 receptor (sIL-6R) signaling [31, 40, 41] .
It is well known that the clinical severity of symptoms during infection is dependent on the genotype and phenotype of the infective organism and that inflammation severity, as assessed by the degree of leukocyte influx, correlates with eventual changes in membrane function [21] . At the cellular level, the temporal nature of the recruitment and subsequent removal of specific leukocyte populations is critical in this respect [31] . The maintenance of activated leukocytes within organs is directly related to increased tissue damage. These data suggest that modulating both the recruitment phase, the residence time, and the timely removal of activated leukocytes might have significant clinical benefit in reducing the inflammatory load within the peritoneal cavity. The timely and effective resolution of inflammation is the hallmark of competent host defense and leads to rapid restoration of organ homeostasis.
Our knowledge of peripheral and peritoneal leukocytes and mesothelial cells has developed considerably over the past 20 years. This knowledge, based partly on measurements in stable PD patients and during peritonitis episodes, has provided a better understanding of the in vivo role of these cell types in peritoneal inflammation and the changing levels of peritoneal inflammatory mediators. In essence, this insight has provided us with tools with which to measure in vivo both peritoneal host defense and inflammatory status during PD, and to enable comparisons between different treatment modalities or different dialysis solutions. This understanding underpins our interpretation of ex vivo data of peritoneal cell function and the levels of markers in effluent that can be used to ascertain the status of host defense, cell function, membrane longevity, and inflammation in PD patients.
UNDERSTANDING THE IMPACT OF PD SOLUTIONS ON MEMBRANE LONGEVITY
Several studies have now clearly identified that degenerative structural changes (both fibrosis and vascular alterations) and alterations in membrane function occur when PD patients are dialyzed with conventional solutions, and that these changes are strongly associated with therapy duration [13, 42, 43] . In the context of PDF, accumulating evidence from both the Biopsy Registry and clinical studies suggest that solution exposure is an important factor contributing to these observed changes [abstract; Craig KJ, J Am Soc Nephrol 12:425A, 2001] [21] . While the precise mechanisms behind these associations are not fully understood, animal studies suggest that exposure to conventional PDF is associated with overproduction of profibrogenic mediators [transforming growth factor (TGF)-b1, and vascular endothelial growth factor (VEGF)] that are strongly implicated in fibrotic diseases of other organ systems [44] [45] [46] [47] [48] [49] . In this context, in vitro data suggest that dysregulated mesothelial cell activation by conventional PDF components contributes to a profibrogenic (and proinflammatory) phenotype. Such in vitro observations have provided the rationale and impetus for ex vivo studies aimed at characterizing not only the in vivo nature of fibrotic and inflammatory changes within the peritoneal environment over time, but also the impact on these changes of treatment with more biocompatible solutions.
UNDERSTANDING THE IMPLICATION OF INCREASED PERITONEAL INFLAMMATION
We have previously discussed how the inflammatory load associated with acute infection appears to contribute to functional changes in the peritoneal membrane [21] . Similarly, morphologic assessment of the parietal peritoneum has correlated fibrotic changes with peritonitis frequency [abstract; Craig KJ, J Am Soc Nephrol 12:425A, 2001] [Williams et al, this supplement]. It is now becoming clear, however, that in addition to the acute effects of peritonitis, chronic local inflammation also is a feature of the peritoneal cavity of PD patients. Studies of inflammatory markers such as hyaluronic acid (HA) and IL-6 have demonstrated that their levels in the dialysis effluent increase with therapy duration [50, 51] . Although the precise factors responsible for this apparent progressive rise in local inflammation are unclear, there is some preliminary evidence that it may be related to dialysis solution exposure [52] . Of interest in this context are observations of increased mesothelial cell secretion of monocyte chemoattractant protein (MCP)-1 following exposure to dialysis solution components (glucose and lactate), because MCP-1 plays a central role in the recruitment of mononuclear cells, which is the hallmark of chronic inflammation in diseases such as arthritis and Crohn's disease [16, 20, 31] . It should be noted that MCP-1 regulation in the peritoneal cavity is under the control of IL-6/sIL-6R signaling [20, 31] , suggesting that IL-6 effluent levels are likely to reflect the inflammatory status of the peritoneum.
EX VIVO STUDIES: DEVELOPMENT AND INTERPRETATION
As discussed previously, although the in vitro characterization of solution biocompatibility profiles has facilitated the identification of potentially negative factors, and to some extent driven new solution design, these studies have provided little direct information on in vivo performance. Studies using spent dialysate isolated from different dwell times with conventional solutions demonstrated that the inhibitory effects of dialysis solutions on leukocytes and mesothelial cells persisted throughout the in vivo dwell period, despite the equilibration of dialysis fluid that occurs with dwell time [11, 53, 54] .
Although several authors have reported studies characterizing predominantly peritoneal macrophages (PMØ) isolated from the uninfected peritoneal cavity [24, 55, 56] , the earliest examination of the function of peritoneal cells isolated from PD patients in the context of dialysis solution exposure were performed in the early 1980s by the group of Verbrugh et al [57] . After initial studies of cell function in acute dwell effluents, this group performed what are now recognized as the first ex vivo study designs, determining the impact of solution pH on the ability of PMØ, isolated from 30-minute dwells, to phagocytose and kill Staphylococcus epidermidis [58] . These pioneering experiments showed unequivocally that neutralizing the pH of conventional PDF resulted in a significant increase in PMØ function, and their subsequent studies showed that both dwell time and solution glucose concentrations were key factors in regulation ex vivo PMØ function [59] [60] [61] (Fig. 1) .
Taken together, these observations provided a key understanding of the in vivo impact of dialysis solutions. These studies reported the first evidence for compromised peritoneal cell function in vivo, showed that the impact on function was dependent on dwell time (see later), and provided the first observation that modulating dialysis solutions (e.g., changing the pH or glucose concentration) resulted in a measurable effect on peritoneal cell function.
EX VIVO STUDIES WITH NEW SOLUTIONS: IMPACT ON PERITONEAL CELL FUNCTION
Although initial ex vivo studies were performed in the early 1990s, their usefulness for in vivo biocompatibility testing of new solutions was not fully realized until the new generation of dialysis solutions buffered with bicarbonate or mixtures of bicarbonate and lactate became available for clinical use almost a decade later.
Reevaluation of the influence of effluent dwell time on ex vivo PMØ function confirmed that early during the dwell the function of both constitutive and stimulated cells was significantly inhibited (Fig. 1) [62] . Earlier in vitro studies had conclusively shown biocompatibility advantages of physiologic pH solutions [63] , and the impact of solution pH was again clearly delineated in these acute dwell experiments [62] . The in vitro studies, however, failed to differentiate between the different buffer compositions in either neutrophil or mesothelial cell function [64] . In the acute ex vivo studies, however, cell function was better maintained with the combination of bicarbonate and lactate, particularly in the presence of high glucose concentrations (3.86% glucose) (Fig. 4) [62] . While these data did not provide the only rationale for the final development of the combined bicarbonate/lactate formulation (Physioneal , Baxter Healthcare Corporation, McGaw Park, IL, USA) [65, 66] , they were important in indicating that the data generated in the ex vivo/in vivo study environment did not always mirror those generated by in vitro assays. The interpretation of these effects are complex but are suggestive of several advantages of the ex vivo approach (Fig. 2) . Subsequent studies followed a different rationale, and were performed as part of the phase II clinical trials of bicarbonate (TB) and bicarbonate/lactate (TBL) dialysis solutions. These studies utilized the acute dwell protocol (30-minute dwell), but were based on repeated assessments of ex vivo PMØ function during a four-week run-in period when patients used conventional solutions, and repeated measurements during a treatment period when they were randomized (for 12 weeks) to continuous dialysis with the control or test solutions. The advantage of this design was the ability to examine the impact both of the solutions and the period of continuous dialysis [67] . These investigations again provided evidence for significantly improved PMØ function (measured as their ability to synthesize TNFa following stimulation) in the presence of neutral pH, with the greatest increment in PMØ function in the bicarbonate/lactate-buffered solution [67] .
One of the perceived weaknesses of the ex vivo approach was the reliance on short-term dwell studies to emphasize the impact of solution pH in modulating cell function [54, 57] . To address this issue and to examine if the improvement in PMØ function was maintained over long periods of continuous dialysis, subsequent studies were performed in overnight dwell effluent (fully equilibrated in terms of pH and electrolyte composition) as part of a Phase III clinical trial of TBL [66] . Peritoneal macrophage function was assessed during the run-in and over the six-month trial period. Consistent with previous observations, continuous dialysis with TBL improved PMØ function compared to treatment with conventional solutions, and this improvement was sustained for the duration of the study [68] .
Taken together, these three studies consistently demonstrated improvements in PMØ function in patients using more biocompatible solutions. While these data do not provide direct evidence of improved host defense (as would be indicated by a reduction in peritonitis rates/incidence, severity, or resolution rate) they suggest a normalization of the peritoneal environment. These data also provide a rationale for clinical studies addressing the key issue of the relationship between dialysis solution composition and susceptibility to peritoneal infection.
EX VIVO STUDIES WITH NEW SOLUTIONS: IMPACT ON THE PERITONEAL ENVIRONMENT
Current knowledge suggests that a number of factors contribute to peritoneal membrane degeneration in PD patients, including infection, the acute inflammation associated with infection, chronic exposure to dialysis solution components, chronic local inflammation, and the systemic inflammation associated with uremia. Insights into the pathophysiology of membrane degeneration have been partly derived from clinical observation and partly by morphologic assessment of peritoneal biopsies [13, 14, 42, 43, 70, 71] . Over the past few years there has been increasing acceptance that the measurement of soluble factors in dialysis effluent can provide valuable information about the biologic status of the peritoneal cavity. This has provided us with the opportunity to widen the scope of ex vivo evaluation of the impact of new PDF on peritoneal biology.
Pioneering work in this area defined changes in peritoneal inflammatory mediators (leukocytes, cytokines, chemokines, and their endogenous inhibitors) during peritonitis [72] [73] [74] [75] [76] [77] . These studies were seminal to our understanding of acute inflammation and underpin our current understanding of the control of these events [31, 41] . At the same time, it was realized that evaluation of effluent markers in stable PD patients might also permit the description of inflammatory and fibrogenic changes that occur over time in the peritoneal membrane [51, [78] [79] [80] .
Initial studies in this area have concentrated on two major areas, the impact on mesothelial integrity and markers of local inflammation within the peritoneal cavity. Cancer antigen 125 (CA125) is a marker of ovarian neoplasia and has long been accepted as a marker of mesothelial cell mass or turnover. In the peritoneal cavity, CA125 is secreted exclusively by these cells [81, 82] . Although there is debate as to the biologic role and regulation of production of CA125, its levels appear to correlate overall with mesothelial cell mass and are thereby an indicator of improved cell integrity and function [78, 79, [83] [84] [85] [86] [87] [88] .
Initial studies examined CA125 expression in PD patients converted from conventional solutions to those with lactate buffer, neutral pH, and low levels of glucose degradation products (GDPs) [89, 90] . These clinical trials demonstrated clearly that conversion to a more physiologic solution was associated with a significant (2-to 3-fold) increase in CA125 levels, findings that were corroborated in more recent studies with a neutral-pH, lactate-buffered solution [91] . As part of the Phase III clinical trail of TBL [66] , CA125 levels in overnight effluent were monitored both in the run-in and the treatment phases of the study. Conversion of patients to TBL was associated with a significant increase (overall 25% increase) in CA125 levels. Interpretation of the data on one level is simple as all studies imply increased mesothelial cell mass in more biocompatible solutions. Given that these cells play a pivotal role in peritoneal host defense and membrane homeostasis, this would appear to provide positive data for the efficacy of these solutions in vivo. The different magnitude of changes with solutions with different design philosophy is more difficult to interpret. On the one hand, a 2-to 3-fold increase in CA125 expression would seem advantageous, but it suggests a similar increase in the number of mesothelial cells that is difficult to accept because the majority were new patients in whom biopsy data suggest the mesothelium should be largely intact (Williams et al, this supplement). Clearly, more data on the expression, complex regulation, and function of this large molecular weight, mucilaginous glycoprotein are required to definitively resolve these issues [92, 93] .
The interpretation of the data on intraperitoneal markers of inflammation would seem more definitive. The process of chronic inflammation is activated within the peritoneal cavity, as evidenced by time-dependent increases in the levels of inflammatory markers such as IL-6, HA, and TNFa in dialysis effluent [50, 51] . The regulation of each of these mediators is well understood, and in the case of IL-6 and TNFa, their role within both acute and chronic inflammation is clearly documented [31, 94, 95] .
Ex vivo effluent studies have measured both HA, TNFa, and IL-6 levels in patients treated with conventional PDF and with TBL [96, 97] . In each case, while the levels of effluent TNFa remained unaltered (and near the detection limit), levels of HA and IL-6 were significantly reduced in patients treated with TBL, following both three and six months of continuous treatment (Fig. 5 ) [96, 97] . The TNFa data indicate that activation of endogenous PMØ function was not increased in a more physiologic environment. The PMØ are the major TNFaproducing cells in the peritoneal cavity and play a central role in host defense [98] . Taken together with the evidence of increased ex vivo PMØ function, the data indicate the increased capacity of these cells to respond when appropriately activated (e.g., during peritonitis onset), but that they are not in a state of permanently in vivo activation and thereby do not contribute to increased local inflammation. Given that PMØ are thought to represent the first line of host defense, normalization of their function would be seen as advantageous. These data are corroborated by observations that PMØ function is aberrant in PD patients using conventional solutions, leading to a more proinflammatory phenotype that develops with time on therapy [99] .
The interpretation of the IL-6 data appears straightforward in the light of recent data indicating its primary role in the control of leukocyte recruitment during inflammation [31, 41, 94] . Reduced levels of IL-6 in the peritoneal cavity of patients using TBL provide evidence of reduced ongoing inflammation. Although the specific cause of reduced IL-6 levels has not been evaluated, its importance in regulating the influx of mononuclear cells (mononuclear phagocytes and lymphocytes), which characterizes both PD and chronic inflammation, is an area that certainly requires further study. In this respect, the association between conventional dialysis solution components and the induction of MCP-1 synthesis, the major chemokine responsible for mononuclear cell recruitment in the peritoneal cavity [33] , and its interrelationship with IL-6 production are clearly of interest [16, 20, 31] .
CONCLUSIONS AND FUTURE PERSPECTIVES
In this review we have attempted to provide a rationale for the use of ex vivo data to evaluate the impact of new solutions (such as Physioneal ) on parameters of peritoneal host defense (cell function), membrane longevity, and local inflammation in PD patients. While these data do not provide definitive evidence of improved patient outcome, they are the first step in defining the in vivo impact of new and more biocompatible solutions.
Accumulating evidence suggests that the use of more biocompatible PDF is associated with significant improvements in the function of cells (primarily PMØ) isolated from the peritoneal cavity. These data are important in two respects: they appear to represent evidence of improved host defense status that is clearly important in the context of the compromised nature of these patients; and if considered as a surrogate for all cell types within the peritoneum, they provide indirect evidence that all peritoneal cell types will have improved function. This latter assumption is supported by the data showing increased CA125 levels (a marker of mesothelial cell integrity) in the presence of biocompatible solutions. It is now well recognized that the mesothelium, with its significant biosynthetic capacity, plays a key role in maintaining peritoneal homeostasis and is pivotal in orchestrating peritoneal host defense and leukocyte recruitment [26, 29, 100] . In long-term PD, there is evidence of alterations in leukocyte phenotype and alteration of mesothelial cell morphology, or even loss of these cells from the peritoneal membrane [13, 99, 101] . Clearly, evidence of preservation/normalization of cell function and viability can be interpreted as a positive aspect of the use of more biocompatible solutions. Our understanding of the peritoneum and its responses has developed rapidly over the past two decades, driven by the use of PD as a therapy and by the science of biocompatibility. Central in this has been the realization that both acute and chronic inflammation, together with dialysis solution components, contribute to peritoneal membrane fibrogenic degeneration, and in some patients limit the lifespan of the membrane (Fig. 3) . Ex vivo evidence using more biocompatible solutions would appear to indicate that many of these degenerative events might be influenced by new solution design. Measurements in dialysis effluent have provided clear evidence of mesothelial cell preservation and reduced intraperitoneal inflammation [90, 96] (Fig. 5) .
Many questions in the field of PD solution biocompatibility remain to be addressed. It is recognized that long-term clinical observations will be necessary to substantiate the in vivo results described above. It is equally recognized that precise interpretation of ex vivo data is difficult, primarily due to our ignorance of many of the cellular and molecular processes that contribute to the membrane changes that occur in PD patients. Over the next decade, our understanding of these processes will inevitably increase, supported by both longitudinal observational studies, collection of clinical data, and basic science. These endeavors will hopefully provide both an expanded understanding of the natural history of the dialyzed peritoneal cavity and a more precise understanding of which factors are prognostic indicators of the health or the degeneration of the peritoneal membrane. 
